Please use this identifier to cite or link to this item:
Title: Omalizumab in chronic spontaneous urticaria: a brazilian real-life experience
Authors: Ensina, Luis Felipe Chiaverini [UNIFESP]
Rodrigues Valle, Solange Oliveira
Juliani, Ana Paula
Galeane, Michel
dos Santos, Rosaly Vieira
Arruda, Luisa Karla
Lima Melo, Janaina Michelle
de Souza, Patricia Karla [UNIFESP]
Serpa, Faradiba Sarquis
de Andrade, Djanira Martins [UNIFESP]
Franca, Alfeu Tavares
Campos, Regis Albuquerque
Camelo-Nunes, Ines [UNIFESP]
Sole, Dirceu [UNIFESP]
Keywords: Urticaria
Issue Date: 2016
Publisher: Karger
Citation: International Archives Of Allergy And Immunology. Basel, v. 169, n. 2, p. 121-124, 2016.
Abstract: Background: Current guidelines on chronic spontaneous urticaria (CSU) suggest a treatment based on a 3-step approach that aims at total symptom control, starting with H1 antihistamines. However, a significant number of patients present an antihistamine-resistant urticaria that must be treated with an alternative third-line therapy such as omalizumab. Methods: Patients with a history of CSU who did not respond to treatment with high doses of modern antihistamines were treated with 150 or 300 mg of omalizumab every 4 weeks. The response to treatment was recorded as complete (CR), partial (PR) or no response. A dose adjustment was proposed according to response. Results: We treated 47 CSU patients with omalizumab (40 females), of whom 39.5% had evidence of autoimmunity. The average number of treatments was 11.4 (range 2-87). All patients had been refractory to high-dose modern antihistamines. A CR was seen in 84.6% of patients who started with 300 mg and in 60% of those who started with 150 mg. Only 1 patient had no response to both the 150- and 300-mg doses. In 6 of the PR patients with 150 mg, a higher dose of 300 mg was proposed and 4 had a CR. Four patients discontinued the treatment. No severe adverse events were reported in the patients who finished the study. Discussion: Although good results were seen in both groups, CR rates were higher in those under a high-dose initial treatment. Our data strongly suggest that the therapy should be individualized. (C) 2016 S. Karger AG, Basel
ISSN: 1018-2438
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.